Reslizumab


( Last Updated : May 4, 2016)
Generic Name:
Reslizumab
Project Status:
Complete
Therapeutic Area:
Asthma, eosinophilic
Manufacturer:
TEVA Canada Innovation
Call for patient/clinician input open:
Brand Name:
Cinqair
Project Line:
Reimbursement Review
Project Number:
SR0495-000
Call for patient/clinician input closed:

Details


Submission Type:
Initial
Indications:
Asthma, eosinophilic
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation: